These 300(+) Biotech Twit­ter cit­i­zens are the quick­est to tweet news


Like many of you, I have a com­pli­cat­ed re­la­tion­ship with Twit­ter. I don’t feel good at it, but here I am ob­sess­ing over it. I re­sent feel­ing like I need to be good at it. That’s a bad way to feel about a re­la­tion­ship you’ve been in for sev­en years.

Your friends have more friends than you do — this is the rub of so­cial net­work­ing. There isn’t a pro­fes­sion­al I know who is proud of the small size of their Rolodex. It’s no won­der so many in bio­phar­ma join Twit­ter on­ly to aban­don it af­ter a few tweets. The de­fault state of their new ac­count ad­ver­tis­es to the world that no­body at all fol­lows what you have to say. That doesn’t feel good ei­ther.

If you work in­side bio­phar­ma, I’ll ad­mit there’s not much rea­son for you to post to Twit­ter. Yes, there are ex­cep­tions and many en­joy a rich­er ca­reer as a re­sult. But it’s not true for a big ma­jor­i­ty. Most knowl­edge in bio­phar­ma is held in the minds and ex­pe­ri­ences of peo­ple and com­pa­nies. These are not shared in pub­lic.

The beau­ty of Twit­ter is that you don’t have to say any­thing at all.

Read-on­ly Twit­ter

The dirty se­cret of Twit­ter is that it’s de­pen­dent on jour­nal­ists and pro­fes­sion­al con­tent-cre­ators. We go to Face­book to see time­lines of our friends and fam­i­ly. LinkedIn time­lines on­ly mat­ter if you’re on a job hunt or re­cruit­ing peo­ple your­self.

Se­ri­ous news hounds turn to Twit­ter be­cause it’s the on­ly se­ri­ous place to craft a hard news time­line. And it turns out “read-on­ly Twit­ter” is quite an amaz­ing prod­uct. When you tune in­to the con­ver­sa­tions of oth­ers, you learn things you didn’t know you need­ed to know.

Jour­nal­ists, brands, and bots all rush to post con­tent the mo­ment it’s fit for con­sump­tion. Some links have legs, oth­ers don’t. It’s an op­er­at­ing sys­tem for the dis­sem­i­na­tion of news and the meta-com­men­tary that fol­lows. This is the top of the pub­lic in­fo pyra­mid. From here these things fil­ter down­stream to the 80% of the in­dus­try who have no re­la­tion­ship with Twit­ter.

Plug­ging your ear in­to the top of this nerve cen­ter gets you clos­er and faster to this in­for­ma­tion. Whether this in­for­ma­tion is good or bad, that’s for you to de­cide. Like the tele­phone game, where you tell some­one some­thing and it changes down­stream, your in­for­ma­tion is pur­er the clos­er it was to the sig­nal. It’s with­out the col­or. No ana­log degra­da­tion.

Too much noise

Hav­ing asym­met­ric in­for­ma­tion is a huge ad­van­tage in busi­ness, right? You know some­thing some­body else doesn’t, and they don’t have ac­cess to those bit of in­fo. This is how it worked in 1990.

In 2016 you can pos­sess asym­met­ric in­for­ma­tion that’s freely avail­able to all, but was lost in the dig­i­tal ether of tweets, press re­leas­es, al­go­spam, and Na­tive Ӓd­ver­tis­ing. In­for­ma­tion is eas­i­ly buried in the con­tent swamp. You just can’t see it all.

Now there’s plen­ty of firms who’ll charge a $10,000 month­ly re­tain­er to sift through these tweets, trav­el ob­scure parts of the web, trav­el be­hind the pay­walls, send you a sum­ma­ry, make sure things don’t fall through the cracks. A few lucky bio­phar­ma ex­ec­u­tives en­joy these perks.

What if you’re brand new to bio­phar­ma? How about if you’re a sea­soned vet but just new to Twit­ter? How do you know who to fol­low? Twit­ter for all in­tents and pur­pos­es is a con­sumer brand. De­spite it be­ing a rich, im­me­di­ate source of in­for­ma­tion for drug de­vel­op­ers, Twit­ter the com­pa­ny has no prod­ucts to on­board such a niche au­di­ence.

We love Twit­ter at End­points and want more peo­ple in bio­phar­ma to en­joy the ben­e­fits of it — even as a pro­fes­sion­al lurk­er.

In­tro­duc­ing Mar­co, our news­bot

Last Au­gust we qui­et­ly launched our vi­ral news­bot@endpts. We re­cent­ly named it Mar­co — con­stant­ly ex­plor­ing BioTwit­ter.

It’s job is to:

  • Search for links in every tweet made in a known uni­verse of thou­sands of BioTwit­ter ac­counts;
  • Cal­cu­late the ve­loc­i­ty of each link shared;
  • If a link starts mov­ing much faster rel­a­tive to oth­er links, it’s now trend­ing;
    • Mar­co then vis­its the link it­self and ex­tracts the head­line, au­thor, and source. We want our own, in­de­pen­dent in­for­ma­tion about the link.
  • Mar­co then tweets the link. It gives cred­it with a hat tip [h/t] to the ac­count that it saw tweet the link first.

It’s that last part that forms the ba­sis of this spe­cial re­port: who was the first per­son to re­port this news?

Mar­co has been read­ing BioTwit­ter 24 hours a day, 7 days a week for al­most a a year now. Over this time we can ag­gre­gate the hat tips Mar­co doled out and come up with this ex­act list.

We guar­an­tee if you fol­low a healthy seg­ment of this list — you’re plugged in­to to heart of the link econ­o­my on BioTwit­ter.

What this list is not

Any­time you rank your friends and col­leagues there’s bound to be hard feel­ings. So let me state for the record:

  • This is not a list of the best ac­counts to fol­low in BioTwit­ter. Many tweeps nev­er post links and in­stead con­tribute with con­text and analy­sis. Mar­co is a few tech­no­log­i­cal rev­o­lu­tions away from be­ing able to un­der­stand when some­one is be­ing sar­cas­tic or help­ful, so it ig­nores text-on­ly tweets. And that’s of­ten the best part of Twit­ter.
  • This is not a who’s who list. There are plen­ty of those around and none of them do any­thing for the per­son who sim­ply wants to be the best pro­fes­sion­al lurk­er on BioTwit­ter.
  • There are no val­ue judge­ments here. This is a pure­ly da­ta-dri­ven list. Yes, it’s our own pro­pri­ety da­ta and I’m not like­ly to di­vulge the ex­act man­ner in which we re­duce the fire­hose of BioTwit­ter in­to a trick­le. But we’re pre­sent­ing the da­ta as-is.


Biotech Twit­ter cit­i­zens most fre­quent­ly cred­it­ed with post­ing trend­ing links first

Over 100 hat tips
John­Cendpts
Fierce­Biotech
Bio­S­tocks
brad­lon­car
Andy­Biotech
adamfeuer­stein
matthe­wher­p­er
phar­malot
Er­ic­Topol
Ben­the­Fi­dler
Fier­cePhar­ma

 

50 – 99 hat tips
Derek­lowe
megtir­rell
Ja­cob­Pli­eth
Mav­er­ick­NY
cru­sadernz
Scrip­Don­naDC
Bos­Biz­Don
ld­tim­mer­man
busi­ness
jonathanrock­off
Reuters_Health
3NT
CGrantWSJ
ste­faniei
LifeSciVC

 

20 – 49 hat tips
Arm­strong­Drew
BioRunUp
reuters­Ben­Hir
Biotech­World
John_LaMat­ti­na
Na­ture­News
car­dio­brief
Lof­tus
an­to­niore­gal­a­do
Jean­neWhalen
ivanoran­sky
Zachary­Bren­nan
Car­o­lineYLChen
AKAarsalan
Emi­ly­W­Fierce
DShay­witz
Black­Swan­Phar­ma
Wrigley­Tom
kris­ten_hal­lam
GideonGil
Bio­DueDili­gence
Reuters­Biz
Car­ly­H­Fierce
WSJbusi­ness
phar­magos­sip
TST­biotech
jq1234t
scrip­news
ZTrac­er
alexlash
ar­lenewein­traub
IPOtweet
WS­JA­sia
bio_clouse­au
FDALawyers
NPRHealth
ByJon­Gard­ner
charlesorn­stein
FDAad­comm
cafephar­ma
PDRen­nert
WSJ
lisam­jarvis
edy­ong209
NE­JM
ju­liaoftoron­to
rplenge
denis­eroland
lo­mu_j

 

At least 10 hat tips
techre­view
Boston­Globe
Reuters
pk­noepfler
WSJhealth
Lau­ra­LandroWSJ
porte­feuille­fun
El­y­se­Tanouye
sdbn
an­drew_ward1
TomBur­ton­WSJ
Ac­tivist­Shorts
Fay­Cortez
Biotech­News
dg­macarthur
dr­bachin­sky
Na­ture­Biotech
zbiotech
cells_nnm
Fes­tivus159
iito­Life­Science
skathire
medtech_ma
US_FDA
genen­tech
DewDili­gence
RNA­i­An­a­lyst
cray­ton_h
FT
vox­dot­com
Scrip­Mandy
car­lz­im­mer
vir­gini­ahugh­es
dhovekamp42
Alec­Gaffney
NYTHealth
PhilSer­afi­no
hmkyale
steveus­din1
fdalaw­blog
The­At­lantic
Scot­tKirsner
IAmBiotech
stem­cel­las­says
TheStal­wart
Trade­Hawk
Bio­Break­out
an­naed­ney
politi­co
ddi­a­mond
sxbe­gle
Frank_S_David
CMichael­Gib­son
Mogu­lAzam
Dr­MiguelPerales
ScripEleanor
Bio­Cen­tu­ry
brentl­saun­ders
rleu­ty_biotech
michael_mezher
ProP­ub­li­ca
rick­berke
Gan­tosJ
Dan­Bud­wick
Phar­ma­ceu­ticBen
FierceMed­Dev
sci­en­tre
srq­s­tock­pick­er
CN­BC

 

At least 4 hat tips
joe­walk­er­WSJ
ethanjweiss
23alo­ha
forbeshealth
GlobeR­obW
EMA_News
sci­ences­can­ner
Ope­nOut­crier
Mike­Huck­man
big3bio­BOS
davies­bj
Mer­ck
mt­md­phd
Drchik23
Med­ical­News
SA_Health­In­vest
db­sable
dan­pri­mack
an­naw­math­ews
guardian­science
Med­ical­New­sUSA
taralach
eval­u­atephar­ma
Ram­sey_Bagh­da­di
westr
ze­ro­hedge
Liq­uid_Biop­sy
Lin_ling_88
dsobek
Ai­ims1742
DrAD­Kline
JNapo­dano
BioWorld
LizSz­abo
BI_Sci­ence
TechCrunch
US­ATO­DAY
not­So­JunkD­NA
ideaphar­ma
Mar­tin­Shkre­li
Evavon­Schaper
mau­reen­m­far­rell
Car­olynyjohn­son
BioTerp
cb­tad­vi­sors
bm­snews
Al­ny­lam
at­ti­cusMB
fund­Duchenne
SashaDamouni
Tim­mer­man­Re­port
bbchealth
bmj_lat­est
Fier­cePhar­mA­sia
biotech­day
FDA_Drug_In­fo
Prop­Thinker
No­var­tis­S­cience
matt_levine
blsuth
FDA­Me­dia
News­from­Science
Sud­han­vaRaj
FiveThir­tyEight
vlad33301
dami­an­garde
BlinkX90
sandiego­science
Mykalt45
Adam­Singer
ScottGot­tlieb­MD
Don­WNi­chol­son
Grady­For­rer
AS­CO
Davi­dAStein­berg
RPM­Re­port­Mike
sloan_ket­ter­ing
Hum­bleBio­Trad­er
JA­MA_cur­rent
Chillz­Trad­ing
SueD­Hell­mann
jay­brad­ner
daph­ne­zo­har
Vikas­Dan­dekarET
cd­weaver
bh­munos
SIRF_Re­port
mslopat­to
michaelscal­ly
michael_gilman
Dougal­lan1
prince­tongb
Drug­Patent­Watch
chris­sy­farr
Za­ck­foot
ma­ki_ki­ta­mu­ra
jfli­er
Life­SciencesMkt
wilbanks
He­len­Bran­swell
afrakt
rt­narch
Ogut_Ozgur
aman­dam­ick­lus
walidgel­lad
smhedge­cock
iBo­nanos
PearlF
jtozz
maryn­m­ck
Dr­Jen­Gunter
Boston_Biotech
broad­in­sti­tute
ES­chat­tner
pi­car­don­health
ScripLu­cie
can­cer­doc­NYC
Xcon­o­my
No­var­tis
hrana
BioWriter­Chik
Nick­PaulTay­lor
WHO
phar­ma­con­nect
myger­sh­berg
gau­tamkol­lu
An­a­lyst­Wire
Econ­SciTech
EP­Clin­i­cal­Tri­al
Bio­Med­Track­er
pe­ter­bach­md
Caulfield­Tim
Mar­i­lyn­Mann
John_Hemp­ton
mbeisen
John­PLeonard­MD
charles_ga­ba
aleszuba­jak
Black­Hawk­Trad­er
JCM­c­Crack­en
Break­ingNews
jodi­gral­nick
eye­onf­da
Robert­Langreth
berna­tolle
cel­lec­tis
Kathy­Giusti
RS_Flinn
Arthur­Ca­plan
bertha­coombs
Lym­phoma_Doc
aaronecar­roll
NIH
NYTScience
Street_In­sid­er
David­Ju­urlink
Na­tRevDrugDisc
ac­taest­fab­u­laXX
23Chromz
EP­Van­tage
Fast­Com­pa­ny
Mau­riceOn­TW
An­nemarieVtW
biotech­baumer
ewan­bir­ney
Jack­West­MD
On­col­o­gy­Times
at­lasven­ture
JPZaragoza1
BioWino
RNA_Biotech
John­Tuck­er­PhD
Col­fax­Cap­i­tal
si­mon­bay­ly
NBC­New­sHealth
fw­phar­ma
In­natePhar­ma
Er­icP­Fierce
thinkgenome
AC­In­vestor­Blog
AlpineBV_Miller
HaertlG
Scrip­Mike­Ward
Roche
at­ul­butte
Na­tureMed­i­cine

Pi­o­neer­ing Click Chem­istry in Hu­mans

Reimagining cancer treatments

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, which is nearly one in six deaths. Recently, we have seen incredible advances in novel cancer therapies such as immune checkpoint inhibitors, cell therapies, and antibody-drug conjugates that have revamped cancer care and improved survival rates for patients.

Despite this significant progress in therapeutic targeting, why are we still seeing such a high mortality rate? The reason is that promising therapies are often limited by their therapeutic index, which is a measure of the effective dose of a drug, relative to its safety. If we could broaden the therapeutic indices of currently available medicines, it would revolutionize cancer treatments. We are still on the quest to find the ultimate cancer medicine – highly effective in several cancer types, safe, and precisely targeted to the tumor site.

Justin Klee (L) and Joshua Cohen, Amylyx co-CEOs (Cody O'Loughlin/The New York Times; courtesy Amylyx)

Ad­vo­cates, ex­perts cry foul over Amy­lyx's new ALS drug, cit­ing is­sues with price, PhI­II com­mit­ment

Not 24 hours after earning the first ALS drug approval in five years, Amylyx Pharmaceuticals’ Relyvrio is already drawing scrutiny. And it’s coming from multiple fronts.

In an investor call Friday morning, Amylyx revealed that it would charge about $158,000 per year, a price point that immediately drew backlash from ALS advocates and some outside observers. The cost reveal had been highly anticipated in the immediate hours after Thursday evening’s approval, though Amylyx only teased Relyvrio would cost less than previously approved drugs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Land­mark Amy­lyx OK spurs de­bate; Some... pos­i­tive? Alzheimer's da­ta; Can­cer tri­al bot­tle­neck; Sanofi's CRISPR bet; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

After brief stops in Paris and Boston, John Carroll and the Endpoints crew are staying on the road in October with their return for a live/streaming EUBIO22 in London. The hybrid event fireside chats and panels on mRNA, oncology and the crazy public market. We hope you can join him there.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Joshua Cohen (L) and Justin Klee, Amylyx co-CEOs

Up­dat­ed: Af­ter long and wind­ing road, FDA ap­proves Amy­lyx's ALS drug in vic­to­ry for pa­tients and ad­vo­ca­cy groups

For just the third time in its 116-year history, the FDA has approved a new treatment for Lou Gehrig’s disease, or ALS.

US regulators gave the thumbs-up to the drug, known as Relyvrio, in a massive win for patients and their families. The approval, given to Boston-area biotech Amylyx Pharmaceuticals, comes after two years of long and contentious debates over the drug’s effectiveness between advocacy groups and FDA scientists, following the readout of a mid-stage clinical trial in September 2020.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Up­dat­ed: Al­ny­lam re­in­forces APOL­LO-B patisir­an da­ta be­fore head­ing to the FDA

Weeks after uncorking some mostly positive data for patisiran in transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, Alnylam is bolstering its package with new exploratory and subgroup data before shipping it off to regulators.

The RNAi drug maintained “generally consistent” benefits in efficacy and quality of life across several prespecified subgroups at month 12, Alnylam announced on Friday afternoon, including age, baseline tafamidis use, ATTR amyloidosis type, baseline six-minute walk test score and others.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Nooman Haque, head of life sciences and healthcare at Silicon Valley Bank, and John Carroll

I’m head­ed to Lon­don soon for #EU­BIO22. Care to join me?

It was great getting back to a live ESMO conference/webinar in Paris followed by a live pop-up event for the Endpoints 11 in Boston. We’re staying on the road in October with our return for a live/streaming EUBIO22 in London.

Silicon Valley Bank’s Nooman Haque and I are once again jumping back into the thick of it with a slate of virtual and live events on October 12. I’ll get the ball rolling with a virtual fireside chat with Novo Nordisk R&D chief Marcus Schindler, covering their pipeline plans and BD work.

#AAO22: J&J’s first look at com­mon eye dis­ease port­fo­lio pads the case for PhII of gene ther­a­py

CHICAGO — While the later-stage drug developers in the geographic atrophy field are near the finish line, Johnson & Johnson’s Janssen is taking a more deliberate route, with a treatment that it hopes to be a one-time fix.

The Big Pharma will take its Hemera Biosciences-acquired gene therapy into a Phase II study later this year in patients with GA, a common form of age-related macular degeneration that impacts about five million people worldwide. To get there, Janssen touted early-stage safety data at the American Academy of Ophthalmology annual conference Saturday morning, half a day after competitors Apellis and Iveric Bio revealed their own more-detailed Phase III analyses.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Jerome Durso, Intercept Pharmaceuticals CEO

In­ter­cep­t's OCA fails a PhI­II NASH tri­al, rais­ing fresh doubts about its years­long quest for an OK

Intercept Pharmaceuticals has run into another big setback in its yearslong quest to win an approval for OCA in NASH. The biotech put out word Friday morning that its Phase III REVERSE study failed the primary endpoint for the liver disease, sending its share price into a tailspin.

There was no significant improvement in fibrosis among the patients suffering from cirrhosis who were treated with obeticholic acid, with investigators hunting for a minimum 1-stage histological improvement in the disease after 18 months of therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Bo Cumbo, new Solid Bio CEO

Sol­id Bio gets a new CEO, $75M cash and drops lead drug as big in­vestors ju­ry-rig a merg­er deal

Three months after Endpoints News broke the story that gene therapy outfit AavantiBio had gutted its CMC group in a reorganization, the biotech’s CEO has helped engineer a merger with struggling penny stock player Solid Bio. And he’s going to remain in charge of the combined operation, as Solid founder Ilan Ganot steps aside.

The merger news this morning features some high-profile investors.

Perceptive Advisors, RA Capital Management and Bain Capital Life Sciences are leading a $75 million raise to add to the pool of cash Solid will have after the tie-up. That will leave Solid $215 million in cash as Bain’s Adam Koppel jumps on the board — enough to pay for ops and get through some key data milestones on their way into 2025.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.